title: Dabigatran in atrial fibrillation: incremental benefit over a time horizon of 5 or 10 years.
authors.forename: Andrea
authors.initials: A
authors.lastname: Messori
authors.forename: Valeria
authors.initials: V
authors.lastname: Fadda
authors.forename: Dario
authors.initials: D
authors.lastname: Maratea
authors.forename: Sabrina
authors.initials: S
authors.lastname: Trippoli
mesh_terms: D000368:Aged; D000925:Anticoagulants / Q000191:economics / Q000627:therapeutic use; D000991:Antithrombins / Q000191:economics* / Q000627:therapeutic use; D001281:Atrial Fibrillation / Q000150:complications*; D001562:Benzimidazoles / Q000191:economics* / Q000627:therapeutic use; D003362:Cost-Benefit Analysis; D000069604:Dabigatran; D006801:Humans; D008390:Markov Chains; D019057:Quality-Adjusted Life Years; D020521:Stroke / Q000517:prevention & control*; D014859:Warfarin / Q000191:economics / Q000627:therapeutic use; D015091:beta-Alanine / Q000031:analogs & derivatives* / Q000191:economics / Q000627:therapeutic use
chemical_list: D000925:Anticoagulants; D000991:Antithrombins; D001562:Benzimidazoles; D015091:beta-Alanine; D014859:Warfarin; D000069604:Dabigatran